Connie L. Batlevi, MD, PhD, discusses the efficacy of tazemetostat in patients with follicular lymphoma and an EZH2 mutation.
Connie L. Batlevi, MD, PhD, a medical oncologist specializing in lymphoma at Memorial Sloan Kettering Cancer Center, discusses the efficacy of tazemetostat (Tazverik) in patients with follicular lymphoma and an EZH2 mutation.
As the investigators expected, patients with the EZH2 mutation had a higher overall response rate with tazemetostat than patients with EZH2 wild-type disease. The patients with wild-type had a longer meaningful duration of response. Although the overall responses were lower in this group, patients who did respond had a duration of response of about a year, according to Batlevi.
Batlevi says these data led researchers to believe there is epigenetic deregulation that is independent of EZH2 mutation status that is being captured by treatment with tazemetostat. This idea needs to be studied further to understand which patients receive the most benefit with tazemetostat, according to Batlevi.
The approval for tazemetostat was 1 of the first mutational-directed therapies for patients with follicular lymphoma. For now, patients with EZH2-mutated disease are more suited for treatment with tazemetostat because they have a target that predisposes them to a heightened response, Batlevi concludes.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More